The treatment of heart failure: The role of neurohumoral activation

Internal Medicine

Volumn 37, Issue 2, 1998, Pages 112-122

  Middlekauff, Holly R ^a   Mark, Allyn L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Angiotensin converting enzyme inhibitors (ACEI); Beta receptor blockers; Digitalis; Exercise training; Renin angiotensin system; Sympathetic nervous system (SNS)

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; VASOPRESSIN;

HEART FAILURE; HUMAN; KINESIOTHERAPY; NORADRENALIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE;

EID: 0031748195     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.112     Document Type: Review

References (68)

1. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, Plasma renin activity, and congestive heart failure: Relations to survival and the effects of therapy in V-Heft II. Circulation 87: V140, 1993.
2. Stevens TL, Burnett JC, Jr, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 95: 1101, 1995.
3. Panina G, Knot UN, Nunziata E, Cody RJ, Binkley PF. Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors. Am Heart J 131: 153, 1996.
4. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82: 1724, 1990.
5. Benedict CR, Weiner DH, Johnstone DE, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunction (SOLVD) registry. The SOLVD investigators. J Am Coll Cardiol 22: 146A, 1993.
6. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M, Mancia G. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92: 3206, 1995.
7. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 95: 169, 1997.
8. Imamura Y, Ando H, Ashihara T, Fukuyama T. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 28: 371, 1996.
9. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 94: 2285, 1996.
10. Dibner-Dunlap ME, Thames MD. Control of sympathetic nerve activity by vagal mechanoreflexes is blunted in heart failure. Circulation 86: 1929, 1992.
11. DiBona GF, Sawin LL. Reflex regulation of renal nerve activity in cardiac failure. Am J Physiol 266: R27, 1994.
12. Middlekauff HR, Hamilton MA, Steven LW, Mark AL. Independent control of skin and muscle sympathetic nerve activity in patients with heart failure. Circulation 90: 1794, 1994.
13. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nerv- ous activity. Circulation 73: 615, 1986.
14. Leimbach WN, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 79: 913, 1986.
15. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL, Kempf JS. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 69: 523, 1992.
16. The CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 316: 1429, 1987.
17. Conn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303, 1991.
18. Fonorow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct vasodilatation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C Trial. J Am Coll Cardiol 19: 842, 1992.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293, 1991.
20. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685, 1991.
21. Pfeffer MA, Braunwald E, Moye LA, et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial (SAVE). N Engl J Med 327: 669, 1992.
22. ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669, 1995.
23. Gruppo Italiano per lo Studio della Sopravvivenza neil'Infart Miocardico. GISSI-3: Effects of lisinopril and transdermal glceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115, 1994.
24. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821, 1993.
25. Chinese Cardiac Study Collaborative Study. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese cardiac study (CCS-1). Lancet 345: 686, 1995.
26. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on the mortality and morbidity after anterior myocardial infarction. N Engl J Med 332: 80, 1995.
27. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730, 1990.
28. Ferrario CM, Gildenber PL, McCubbin JW. Cardiovascular effects of angiotensin mediated by the central nervous system. Circ Res 30: 257, 1972.
29. Gerken VM, Santos RA. Centrally infused bradykinin increases baroreceptor reflex sensitivity. Hypertension 19: II-176, 1992.
30. Dibner-Dunlap ME, Smith ML, Kinugawa T, Thames MD. Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure. J Am Coll Cardiol 27: 358, 1996.
31. Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 96: 1173, 1997.
32. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38: 1085, 1997.
33. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 27: 714, 1996.
34. Pitt B, Segal R, Martinez FA, et al., on behalf of ELITE Study Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study. ELITE). Lancet 349: 747, 1997.
35. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022, 1975.
36. Waagstein F, Caidahl K, Wallentin I, Bergh C-H, Hjalmarson A. Long term beta-blockade in dilated cardiomyopathy: effects of short and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551, 1989.
37. Swedberg K, Waagstein F, Hjalmarson A, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1: 1374, 1979.
38. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441, 1993.
39. CIBIS Investigators and Committees. A randomized trial of beta-block ade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS). Circulation 90: 1765, 1994.
40. Packer M, Colucci WS, Sackner-Berstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94: 2793, 1996.
41. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular function, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817, 1996.
42. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilil Heart Failure Study Group. The effect of carvedilol on morbidity and mortality inpatients with chronic heart failure. N Engl J Med 334: 1349, 1996.
43. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94: 2807, 1996.
44. Pfeffer MA, Stevenson LW. β-adrenergic blockers and survival in heart failure. K Engl J Med 334: 1396, 1996.
45. Yoshikawa T, Port JD, Asano K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 17 (suppl B): 8, 1996.
46. Sponer G, Bartsch W, Strein K, Muller-Beckman B, Boehm E. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypolensive properties. J Cardiovasc Pharmacol 9: 317, 1987.
47. Wallin BG, Sundolf G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 6: 557, 1984.
48. Rahman MA, Hara K, Daly PA, Wigle ED, Floras JS. Reduction in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy: preliminary observations. Br Heart J 74: 431, 1995.
49. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 329: 1, 1993.
50. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. J Am Coll Cardiol 22: 955, 1993.
51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 336: 525, 1997.
52. Thames MD, Waickman LA, Abboud FM. Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin. Am J Physiol 239: H628, 1980.
53. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 80: 65, 1989.
54. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 28: 155, 1996.
55. Thames MD, Miller BD, Abboud FM. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol 243: H815, 1982.
56. Brouwer J, van Veldhuisen DJ, Veld AJM, Dunselman PHJM, Boomsma F, Haaksma J, Lie KI. Heart rate variability in patients with mild to moderate heart failure: Effects of neurohormonal modulation by digoxin and ibopamine. J Am Coll Cardiol 26: 983, 1995.
57. McKelvie RS, Teo KK, McCartney N, Human D, Montague T, Yusuf S. Effects of exercise training in patients with congestive heart failure: A critical review. J Am Coll Cardiol 25: 789, 1995.
58. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 85: 1751, 1992.
59. Zelis R, Longhurst J, Capone RJ, Mason DT. A Comparison of regional blood flow and oxygen utilization during dynamic forearm exercise in normal subjects and patients with congestive heart failure. Circulation 50: 137, 1974.
60. Coats AJS, Adamopoulos S, Meyer TE, Conway J, Sleight P. Effects of physical training in chronic heart failure. Lancet 335: 63, 1990.
61. Coats AJS, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 85: 2119, 1992.
62. Keteyian SJ, Levine AB, Brawner CA, et al. Exercise training in patients with heart failure. A randomized, rontrolled trial. Ann Intern Med 124: 1051, 1996.
63. Meyer K, Görnandt L, Schwaibold, et al. Predictors of response to exercise training in severe chronic congestive heart failure. Am J Cardiol 80: 56, 1997.
64. Lee AP, Ice R, Blessy R, Sanmarco ME. Long-term effects of physical training on coronary patients with impaired ventricular function. Circulation 60: 1519, 1979.
65. Kiilavuori K, Toivonen L, Näveri H, Leinon H. Reversal of autonomic derangements by physical training in chronic heart failure assessed by heart rate variability. Eur Heart J 16: 490, 1995.
66. Adamopoulos S, Ponikowski P, Cerquetani E, Piepoli M, Rosano G, Sleight P, Coats AJS. Circadian pattern of heart rate variability in chronic heart failure patients. Eur Heart J 16: 1380, 1995.
67. Toepfer M, Meyer K, Maier P, Dambacher M, Theisen K, Roskamm H, Frey AW. Influence of exercise training and restriction of activity on autonomie balance in patients with severe congestive heart failure. Clin Sci 91 (Suppl): 116, 1996.
68. Hara K, Floras JS. After-effects of exercise on haemodynamics and muscle sympathetic nerve activity in young patients with dilated cardiomyopathy. Heart 75: 602, 1996.